Scientists at the University of California San Diego have announced results from a landmark clinical trial demonstrating that the experimental drug ION224 can dramatically reduce liver fat and inflammation in patients suffering from metabolic dysfunction-associated steatohepatitis, commonly known as MASH. The condition, which affects an estimated 25 million Americans and hundreds of millions worldwide, currently has extremely limited treatment options and frequently progresses to cirrhosis, liver failure, and the need for organ transplantation.
The Phase 2 clinical trial, published in The Lancet, enrolled 280 patients with biopsy-confirmed MASH across 45 medical centers in the United States and Europe. Patients receiving ION224 through subcutaneous injection every four weeks showed a remarkable 50 percent average reduction in liver fat content after 48 weeks of treatment, compared to just 7 percent in the placebo group. More importantly, 35 percent of treated patients achieved complete resolution of steatohepatitis with no worsening of liver fibrosis, a milestone that researchers described as unprecedented for any MASH therapeutic candidate.
ION224 works through a novel mechanism of action targeting a protein called DGAT2, which plays a critical role in the synthesis of triglycerides within liver cells. By selectively inhibiting the production of this enzyme using antisense oligonucleotide technology, the drug reduces the accumulation of fat in liver tissue without the systemic side effects associated with other lipid-lowering approaches. Dr. Rohit Loomba, the principal investigator and director of the MASH Clinical Research Center at UC San Diego, explained that this targeted approach represents a fundamental shift in how clinicians may treat the disease.
MASH has emerged as one of the most pressing liver health crises of the 21st century, driven largely by rising rates of obesity, type 2 diabetes, and metabolic syndrome. Unlike simple fatty liver disease, which is generally benign, MASH involves active inflammation and progressive damage to liver cells that can lead to irreversible scarring. Until recently, no pharmaceutical treatments had demonstrated the ability to both reduce liver fat and reverse the inflammatory process simultaneously. The only previously approved drug for MASH, resmetirom, addresses a different pathway and has shown more modest efficacy in certain patient populations.
The safety profile of ION224 proved encouraging throughout the trial. The most common side effects were mild injection site reactions, reported in approximately 15 percent of participants, and temporary reductions in platelet counts that remained within clinically acceptable ranges. No serious adverse events were attributed to the drug, and discontinuation rates were comparable between the treatment and placebo groups. Researchers noted that the once-monthly dosing schedule offers a significant advantage over daily oral medications, potentially improving patient compliance in a disease that requires long-term management.
Beyond its effects on liver fat, ION224 demonstrated meaningful improvements in several metabolic biomarkers. Patients in the treatment group experienced significant reductions in serum triglyceride levels, liver enzyme concentrations, and markers of systemic inflammation. These secondary findings suggest that the drug may provide broader metabolic benefits beyond liver-specific effects, potentially reducing cardiovascular risk in a patient population already prone to heart disease and stroke.
Ionis Pharmaceuticals, the company developing ION224, has announced plans to initiate a large-scale Phase 3 trial in the fourth quarter of 2026, with the goal of seeking regulatory approval from the U.S. Food and Drug Administration by 2029. If successful, ION224 could become one of the most impactful liver disease treatments developed in decades, addressing an enormous unmet medical need for millions of patients worldwide who currently have few effective options beyond lifestyle modifications and weight loss surgery.
Comments